ABTB2

Chr 11

ankyrin repeat and BTB domain containing 2

Also known as: ABTB2A, BTBD22, CCA3

Predicted to enable protein heterodimerization activity. Predicted to act upstream of or within cellular response to toxic substance. [provided by Alliance of Genome Resources, Jul 2025]

ResearchGenerating clinical summary…

Clinical highlights

Interpreting a novel variant
This gene is strongly intolerant of loss-of-function variation in the population, so LoF variants warrant close attention. No curated mechanism annotation is available — see the mechanism card for the computational prediction and its caveats.Based on population constraint only.
0
Active trials
2
Pubs (1 yr)
P/LP submissions
P/LP missense
0.46
LOEUF
Mechanism
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint?
0.46LOEUF
pLI 0.005
Z-score 4.38
OE 0.29 (0.190.46)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?
1.23Z-score
OE missense 0.86 (0.800.92)
516 obs / 600.6 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.29 (0.190.46)
00.351.4
Missense OE?0.86 (0.800.92)
00.61.4
Synonymous OE?0.93
01.21.6
LoF obs/exp: 13 / 44.5Missense obs/exp: 516 / 600.6Syn Z: 0.94

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

ABTB2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →